Benefit Medical Methods, Inc. MMSI reported third-quarter 2025 adjusted earnings per share (EPS) of 92 cents, up 6.9% from the year-ago quarter. The underside line surpassed the Zacks Consensus Estimate by 12.2%.
GAAP EPS for the quarter was 46 cents, down 4.2% 12 months over 12 months.
MMSI’s Income Particulars
Revenues grossed $384.2 million within the reported quarter, up 13% 12 months over 12 months on a reported foundation. The metric topped the Zacks Consensus Estimate by 3.5%.
Whole revenues at fixed change fee (CER) elevated 12.5% 12 months over 12 months, whereas CER, natural revenues elevated 7.8%.
Benefit Medical’s Geographic Outcomes
The U.S. gross sales amounted to $230.6 million, which elevated 11.7% 12 months over 12 months on a reported foundation and 12.1% at CER. This determine compares to our third-quarter projection of $221.1 million.
Worldwide gross sales amounted to $153.6 million, up 15.2% 12 months over 12 months on a reported foundation and 13.1% at CER. This determine compares to our third-quarter projection of $148.3 million.
Revenues from the Asia-Pacific area have been $64.9 million, up 7.4% 12 months over 12 months on a reported foundation and seven.7% at CER. This determine compares to our third-quarter projection of $62.5 million.
Revenues from Europe, the Center East and Africa area have been $71.5 million, up 22.3% and 17.5% 12 months over 12 months on a reported foundation and CER, respectively. This determine compares to our third-quarter projection of $67 million.
Revenues from the Remainder of World area have been $17.2 million, up 18.5% and 17.8% 12 months over 12 months on a reported foundation and CER, respectively. This determine compares to our third-quarter projection of $18.8 million.
MMSI’s Segmental Particulars
Benefit Medical operates by two segments — Cardiovascular and Endoscopy.
The Cardiovascular unit reported third-quarter revenues of $366.4 million, up 13.5% on a reported foundation and 12.9% at CER 12 months over 12 months. This determine compares to our segmental projection of $350.7 million for the third quarter.
The Cardiovascular section consists of the next product classes: Peripheral Intervention (PI), Cardiac Intervention (CI), Customized Procedural Options (CPS) and authentic gear producer (OEM).
PI product line revenues have been $144.8 million, up 8.8% on a reported foundation and eight.3% at CER 12 months over 12 months. This compares to our projection of $147.5 million.
CI revenues of $116.7 million rose 29.3% on a reported foundation and 28.5% at CER 12 months over 12 months. This compares to our projection of $106 million.
CPS revenues elevated 7.3% on a reported foundation and 6.4% at CER 12 months over 12 months to $54.1 million. This compares to our projection of $51 million.
OEM revenues improved 3.6% on a reported foundation and three.3% at CER 12 months over 12 months to $50.8 million. This compares to our projection of $46.1 million.
Endoscopy units’ revenues totaled $17.7 million, up 4.4% 12 months over 12 months on a reported foundation and 4.3% at CER. This determine compares to our segmental projection of $18.7 million for the third quarter.
Benefit Medical Methods, Inc. Worth, Consensus and EPS Shock
Benefit Medical Methods, Inc. price-consensus-eps-surprise-chart | Benefit Medical Methods, Inc. Quote
Benefit Medical’s Margin Evaluation
Within the quarter below assessment, Benefit Medical’s gross revenue elevated 18.3% 12 months over 12 months to $186.4 million. The gross margin expanded 217 foundation factors (bps) to 48.5%. We had projected a forty five.4% gross margin for the third quarter.
Promoting, normal & administrative bills elevated 20.2% 12 months over 12 months to $119.8 million. Analysis and improvement bills rose 16.8% 12 months over 12 months to $23.9 million. Adjusted working bills of $143.8 million rose 19.6% 12 months over 12 months.
Adjusted working revenue totaled $42.6 million, reflecting a 14.1% enhance from the prior-year quarter. The adjusted working margin within the third quarter expanded 11 bps to 11.1%.
MMSI’s Monetary Place
Benefit Medical exited third-quarter 2025 with money and money equivalents of $392.5 million in contrast with $341.8 million on the second-quarter finish. Whole long-term debt on the finish of third-quarter 2025 was $732.9 million in contrast with $731.8 million on the second-quarter finish.
Cumulative web money offered by working actions on the finish of third-quarter 2025 was $198.9 million in contrast with $152.1 million a 12 months in the past.
Benefit Medical’s Steering
MMSI has raised its outlook for 2025.
Web revenues for 2025 are actually projected to be between $1.502 billion and $1.515 billion (reflecting a rise of 10.7%-11.7% on a reported foundation over the comparable reported figures of 2024), up from the prior outlook of $1.495 billion and $1.507 billion (reflecting a rise of 10.2%-11.1% on a reported foundation over the comparable reported figures of 2024). The Zacks Consensus Estimate is pegged at $1.50 billion.
Revenues are actually anticipated to be up 10.3%-11.2% at CER in 2025, up from the prior outlook of 9.7% -10.6% over the comparable figures of 2024.
Web revenues from the Cardiovascular section are actually anticipated to be within the vary of $1.430 billion-$1.441 billion (representing a rise of 10%-11% over the comparable reported figures of 2024), up from the earlier outlook of $1.423 billion-$1.434 billion (representing a rise of 9%-10% over the comparable reported figures of 2024).
The Endoscopy section’s web revenues are actually projected to be between $72 million and $74 million (representing a rise of 32%-34% over the comparable reported figures of 2024), wider than the sooner steerage of $72 million and $73 million (representing a rise of 32%- 34% over the comparable reported figures of 2024).
Adjusted EPS for 2025 is now projected to be within the vary of $3.66-$3.79 (representing a rise of 6%-10% over the comparable reported figures of 2024), up from the prior outlook of $3.52-$3.72 (representing a rise of two%-8% over the comparable reported figures of 2024). The Zacks Consensus Estimate is pegged at $3.63.
Our Tackle MMSI
Benefit Medical exited the third quarter of 2025 with better-than-expected outcomes. The year-over-year uptick within the prime line was spectacular. The corporate noticed income progress in each its segments and all of the product classes inside its Cardiovascular unit. Sturdy income progress in the US and out of doors was spectacular. The growth of each margins bodes nicely for the inventory.
In October, Benefit Medical signed a definitive asset buy settlement with Pentax of America, Inc., a subsidiary of PENTAX Medical, Inc., to accumulate the C2 CryoBalloon system and associated expertise. MMSI, in September, introduced that Embosphere Microspheres are actually indicated within the European Union to be used in genicular artery embolisation to deal with sufferers with knee osteoarthritis. In August, the corporate introduced the U.S. industrial launch of the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Securement Know-how. These look promising for the inventory.
Nevertheless, the continued challenges associated to the dynamic and unsure international macroeconomic setting increase our concern.
Benefit Medical’s Zacks Rank and Different Key Picks
Benefit Medical at present has a Zacks Rank #2 (Purchase).
A number of different top-ranked shares within the broader medical area which have introduced quarterly outcomes are Boston Scientific Company BSX, GE HealthCare Applied sciences Inc. GEHC and Intuitive Surgical, Inc. ISRG.
Boston Scientific, carrying a Zacks Rank of two, reported third-quarter 2025 adjusted EPS of 75 cents, beating the Zacks Consensus Estimate by 5.6%. Revenues of $5.07 billion outpaced the consensus mark by 1.9%. You may see the entire record of as we speak’s Zacks #1 Rank (Robust Purchase) shares right here.
Boston Scientific has a long-term estimated progress fee of 16.4%. BSX’s earnings surpassed estimates in every of the trailing 4 quarters, the common shock being 7.4%.
GE HealthCare reported third-quarter 2025 adjusted EPS of $1.07, beating the Zacks Consensus Estimate by 1.9%. Revenues of $5.14 billion surpassed the Zacks Consensus Estimate by 1.5%. It at present carries a Zacks Rank #2.
GE HealthCare has a long-term estimated progress fee of 5.8%. GEHC’s earnings surpassed estimates in every of the trailing 4 quarters, the common shock being 11.1%.
Intuitive Surgical reported third-quarter 2025 adjusted EPS of $2.40, beating the Zacks Consensus Estimate by 20.6%. Revenues of $ 2.51 billion surpassed the Zacks Consensus Estimate by 3.9%. It at present carries a Zacks Rank #2.
Intuitive Surgical has a long-term estimated progress fee of 15.7%. ISRG’s earnings surpassed estimates in every of the trailing 4 quarters, the common shock being 16.3%.
Boston Scientific Company (BSX) : Free Inventory Evaluation Report
Intuitive Surgical, Inc. (ISRG) : Free Inventory Evaluation Report
Benefit Medical Methods, Inc. (MMSI) : Free Inventory Evaluation Report
GE HealthCare Applied sciences Inc. (GEHC) : Free Inventory Evaluation Report
This text initially printed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
